Investors sure do like Merck's
Interestingly, they still don't seem to be ascribing much value to vintafolide or the rest of Endocyte's pipeline. The biotech had $128 million at the end of the year and got another $120 million from Merck in the licensing deal. It's certainly spent some in the first part of the year but should still have around $230 million pro forma, and the company has a market cap of only $275 million.
Sure, Endocye is going to spend much of that $230 million before it's cash flow-positive from sales and royalties; the phase 3 ovarian cancer trial for vintafolide, which Endocyte is still primarily responsible for, is expected to cost $40 million. Endocyte will also need to spend money setting up a commercial infrastructure in Europe, if it's approved there, since Endocyte retained the rights to sell the companion diagnostic for vintafolide. And then there's the pipeline of early stage drugs, which will suck resources for years to come.
But there's potential for more cash to come in from Merck. The deal calls for up to another $880 million in development, regulatory, and commercialization milestones. Unfortunately for investors, the company didn't break it out further, so there's no way to know when the cash might come in.
The choice of Merck is an interesting one, since the pharma isn't really an oncology powerhouse. None of the top-selling drugs it breaks out sales for on its earnings releases is a cancer drug. In Merck's pipeline, there's ARIAD Pharmaceuticals'
Ron Ellis, Endocyte's president and CEO, said there were "a lot of companies" interested in licensing vintafolide, so maybe it's just a case where the money was too good to turn down. Partnering with Eli Lilly
Overall, the deal looks good and should help prevent shareholder dilution for the foreseeable future. I'm inclined to say Endocyte is undervalued even after the jump, but that's a long-term call; don't be surprised to see some weakness in the short term, as often happens with biotechs with no near-term catalysts.
Fool contributor Brian Orelli holds no position in any company mentioned. Check out his holdings and a short bio. Motley Fool newsletter services have recommended buying shares of Pfizer. The Motley Fool has a disclosure policy. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.
More from The Motley Fool
What Happened in the Stock Market Today
On a day stocks bounced up and down, shares of Energizer Holdings rose on acquisition news, and Merck reported positive results in a lung cancer trial.
These 3 Dividend Giants Are Safer Than You Think
Concerns about these stocks and their dividends are overblown.
Why 2017 Was a Year to Forget for Merck & Co. Inc.
Everything looked OK for the drugmaker until Merck delivered an unwelcome October surprise.